---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-011885"
form_type: "8-K"
ticker: "IBIO"
cik: "0001420720"
company_name: "iBio, Inc."
filed_at: "2025-09-05T23:59:59+00:00"
generated_at: "2026-05-17T07:55:32.540185+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# iBio FY2025 revenue $0.4M, cash $8.8M; advances obesity pipeline with IBIO-610 fat loss data

## Summary
- Revenue $0.4M (up $0.2M YoY); R&D expense $8.3M (+$3.1M); G&A $10.7M (-$1.0M).
- Cash $8.8M at June 30; raised $6.2M warrant inducement; closed $50M public offering (potential +$50M on warrant exercise).
- IBIO-610 (activin E) showed 26% fat mass reduction with no lean mass loss in mice; NHP study initiated.
- IBIO-600 (anti-myostatin) NHP PK data demonstrated extended half-life and dose-dependent muscle growth.
- Collaboration with AstralBio yielded amylin receptor antibody reducing acute food intake 60% in obese mice.

## SEC filing metadata
- accession: 0001558370-25-011885
- form_type: 8-K
- ticker: IBIO
- cik: 0001420720
- company_name: iBio, Inc.
- filed_at: 2025-09-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1420720/000155837025011885/0001558370-25-011885-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1420720/000155837025011885/ibio-20250905x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-011885
- JSON: https://secwatch.observer/filing/0001558370-25-011885.json
- Plain text: https://secwatch.observer/filing/0001558370-25-011885.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.